AngioWaveNet vs EchoNext
AI Verdict
Choose AngioWaveNet if…
Choose AngioWaveNet if your cardiac catheterization lab seeks to enhance real-time vessel visualization during interventional procedures. Its AI-powered spatiotemporal enhancement improves the clarity of fluoroscopic angiograms, integrating seamlessly with existing workflows and any angiography system to provide clearer anatomical detail for improved procedural guidance.
View AngioWaveNet →Choose EchoNext if…
Choose EchoNext if your practice or hospital aims to non-invasively screen for hidden structural heart disease using standard ECGs. This AI tool is ideal for broad access, from major hospitals to community practices, to detect conditions like heart failure, valve disease, and pulmonary hypertension, providing crucial diagnostic support at an early stage.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AngioWaveNet | EchoNext |
|---|---|---|
| Pricing | Pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. custom packages are available. | Starts at $600/month |
| Deployment | Cloud-based or on-premise/servers | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AngioWaveNetAngioWaveNet emphasizes a 'light footprint' and minimal training, integrating seamlessly as a DICOM endpoint within existing Cath lab workflows. It processes images automatically post-acquisition, allowing clinicians to review original and enhanced versions side-by-side without procedural delays. EchoNext's deployment through the OpenEvidence platform suggests ease of access, but AngioWaveNet's direct integration and minimal training requirements give it an edge in immediate workflow adoption.
Clinical Value
EchoNextEchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI. It has been validated in extensive studies and has a published case where its detection led to a heart transplant. While AngioWaveNet enhances visualization, EchoNext offers a new screening paradigm for early disease detection.
Pricing & Value
TieAngioWaveNet offers annual licensing or subscription-based access tailored to cath lab volume and hospital needs, with custom packages available. EchoNext provides tiered pricing starting at $600/month, with an implementation fee and annual discount options. Both offer flexible models, but without specific pricing details for AngioWaveNet or a clear understanding of the 'value' of each tier for EchoNext, a direct comparison of cost-effectiveness is difficult.
Enterprise Readiness
EchoNextEchoNext is available through the OpenEvidence clinical decision support platform, which is used by over half of US clinicians and has agreements with major health systems. This broad platform integration and existing partnerships suggest strong enterprise readiness. AngioWaveNet offers cloud-based or on-premise deployment and HIPAA compliance, but lacks the documented widespread platform integration of EchoNext.
Innovation
EchoNextEchoNext is the first FDA-cleared AI tool to detect six types of structural heart disease from standard ECGs, a groundbreaking application that can identify hidden conditions earlier than traditional methods. AngioWaveNet's AI-powered spatiotemporal enhancement is innovative for improving angiogram visualization, but EchoNext's ability to detect previously undetectable conditions from a common, inexpensive test represents a more significant paradigm shift in cardiac screening.
Support & Docs
TieBoth tools are FDA-cleared and HIPAA compliant, implying a level of regulatory documentation and adherence. AngioWaveNet mentions minimal training and cybersecurity testing, while EchoNext's availability on OpenEvidence suggests platform-level support. However, neither provides explicit details on ongoing customer support, training programs, or publicly available comprehensive documentation beyond their core functionalities.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AngioWaveNet | EchoNext |
|---|---|---|
| Name | AngioWaveNet | EchoNext |
| Company | Angiowave Imaging | Pathway Labs |
| Description | FDA-cleared AI software that enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories, integrating with existing Cath lab workflows. | FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Functionality | AI-powered Spatiotemporal Enhancement Processing (STEPu2122); Improved vessel visualization in fluoroscopic angiograms; Integrates with existing Cath lab workflows; Compatible with any fluoroscopic angiography system (vendor-agnostic); Post-processing AI for angiographic images; Enhances visibility of blood vessels, vascular structures, and anatomical features; Functions as a DICOM endpoint for imaging systems. | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; Non-invasive diagnostic support. |
| Specialties | Cardiology, Interventional Radiology, Vascular Surgery | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
| Target Data Input | Fluoroscopic angiograms | Standard 12-lead ECGs |
Videos
Demos, reviews, and walkthroughs featuring AngioWaveNet and EchoNext.